Skip to main content
SpringerLink
Log in

Vasopressin Receptors in Voiding Dysfunction

  • Chapter
  • First Online:
Urinary Tract

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 2011))

Abstract

Arginine vasopressin (AVP), also known as vasopressin or anti-diuretic hormone, is a neuropeptide produced in the hypothalamus. It is primarily responsible for osmoregulation and thus maintains body fluid homeostasis. It is also a potent vasoconstrictor, may have a role in higher cognitive functions and affects metabolism. All the biological and cellular effects of vasopressin are mediated by the interaction of this hormone with three G-protein-coupled receptors – V1a, V1b and V2.Urological applications are based on the rationale that V2 receptors mediate water conservation and increase urine osmolality. Due to their anti-diuretic properties mediated by the V2 receptors, synthetic vasopressin agonists, such as desmopressin, are now commonly used for the treatment of nocturnal polyuria, central diabetes insipidus and nocturnal enuresis and potentially in urinary incontinence. Desmopressin has been licenced worldwide for haematological indications of haemophilia and von Willebrand disease. Vasopressin receptor antagonists correct hyponatremia by blocking the activation of the V2 receptor and induce a free water diuresis without an accompanying natriuresis or kaliuresis; an effect termed ‘aquaresis’. Interfering with vasopressin signalling by administering vasopressin antagonists may have clinical benefits in acute and chronic heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abu-Basha EA, Yibchok-anun S, Hsu WH (2002) Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51:1184–1190

    Article  CAS  PubMed  Google Scholar 

  • Acher R, Light A, Du Vigneaud V (1958) Purification of oxytocin and vasopressin by way of a protein complex. J Biol Chem 233(1):116–120

    CAS  PubMed  Google Scholar 

  • Agre P, Preston GM, Smith BL, Jung JS, Raina S, Moon C, Guggino WB, Nielsen S (1993) Aquaporin CHIP: the archetypal molecular channel. Am J Physiol 265:F463–F476

    CAS  PubMed  Google Scholar 

  • Agre P, Bonhivers M, Borgnia MJ (1998) The aquaporins, blueprints for cellular plumbing systems. J Bio Chem 273:14659–14662

    Article  CAS  Google Scholar 

  • Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation. Regul Pept 96:23–29

    Article  CAS  PubMed  Google Scholar 

  • Alloussi SH, Mürtz G, Lang C, Madersbacher H, Strugala G, Seibold J, Schwentner C, Stenzl A, Alloussi S. Desmopressin treatment regimens in monosymptomatic and nonmonosymptomatic enuresis: a review from a clinical perspective. J Pediatr Urol. 2010 [Epub] Accessed 01st August 2010

    Google Scholar 

  • Antoni FA, Holmes MC, Makara GB, Kárteszi M, László FA (1984) Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 5(3):519–522

    Article  CAS  PubMed  Google Scholar 

  • Arai Y, Fujimori A, Sasamata M, Miyata K (2009) New topics in vasopressin receptors and approach to novel drugs: research and development of Conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. J Pharmacol Sci 109:53–59

    Article  CAS  PubMed  Google Scholar 

  • Asplund R, Sundberg B, Bengtsson P (1998) Desmopressin for the treatment of nocturnal polyuria in the elderly: a dose titration study. Br J Urol 82(5):642–646, Level 2b

    CAS  PubMed  Google Scholar 

  • Asplund R, Sundberg B, Bengtsson P (1999) Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int 83:591–595 (Level 1b)

    Article  CAS  PubMed  Google Scholar 

  • Bae JH, Oh MM, Shim KS, Cheon J, Lee JG, Kim JJ, Moon DG (2007) The effects of long-term administration of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: a circadian study. J Urol 178(1):200–203

    Article  CAS  PubMed  Google Scholar 

  • Bernat A, Hoffmann T, Dumas A et al (1997) V2 receptor antagonism of DDAVP-induced release of hemostatis factors in conscious dogs. J Pharmacol Exp Ther 282:597–602

    CAS  PubMed  Google Scholar 

  • Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 11(10):406–410

    Article  CAS  PubMed  Google Scholar 

  • Birumachi JI, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A (2007) Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol 566:226–230

    Article  CAS  PubMed  Google Scholar 

  • Böselt I, Römpler H, Hermsdorf T, Thor D, Busch W et al (2009) Involvement of the V2 vasopressin receptor in adaptation to limited water supply. PLoS One 4(5):e5573. doi:10.1371/journal.pone.0005573. Accessed online on 26th July, 2009

    Article  PubMed  Google Scholar 

  • Burgu B, Gökce MI, Gücük A, Soygür T (2009) Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in male monosymptomatic enuretic adults. Urology 74(4):915–919

    Article  PubMed  Google Scholar 

  • Burroughs AK (1998) Pharmacological treatment of acute variceal bleeding. Digestion 59:28–36

    Article  CAS  PubMed  Google Scholar 

  • Cabiaux V, Oberg KA, Pancoska P, Walz T, Agre P, Engel A (1997) Secondary structures comparison of aquaporin-1 and bacteriorhodopsin: a Fourier transform infrared spectroscopy study of two-dimensional membrane crystals. Biophys J 73:406–417

    Article  CAS  PubMed  Google Scholar 

  • Caione P, Nappo S, De Castro R, Prestipino M, Capozza N (1999) Low-dose desmopressin in the treatment of nocturnal urinary incontinence in the exstrophy–epispadias complex. BJU Int 84(3):329–334

    Article  CAS  PubMed  Google Scholar 

  • Caldwell HK, Lee HJ, Macbeth AH, Young WS (2008) Vasopressin: behavioral roles of an ‘original’ neuropeptide. Prog Neurobiol 84(1):1–24

    Article  CAS  PubMed  Google Scholar 

  • Cannon A, Carter PG, McConnell AA, Abrams P (1999) Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int 84:20–24, Level 1b

    Article  CAS  PubMed  Google Scholar 

  • Chancellor MB, Rivas DA, Staas WE Jr (1994) DDAVP in the urological management of the difficult neurogenic bladder in spinal cord injury: preliminary report. J Am Paraplegia Soc 17(4):165–167

    CAS  PubMed  Google Scholar 

  • Chancellor MB, Atan A, Rivas DA, Watanabe T, Tai HL, Kumon H (1999) Beneficial effect of intranasal desmopressin for men with benign prostatic hyperplasia and nocturia: preliminary results. Tech Urol 5(4):191–194 (Level 2b)

    CAS  PubMed  Google Scholar 

  • Cheng A, van Hoek AN, Yeager M, Verkman AS, Mitra AK (1997) Three-dimensional organization of a human water channel. Nature 387:627–630

    Article  CAS  PubMed  Google Scholar 

  • Cridland RA, Kasting NW (1992) A critical role for central vasopressin in regulation of fever during bacterial infection. Am J Physiol 263:R1235–R1240

    CAS  PubMed  Google Scholar 

  • Dantzer R, Bluthé RM (1993) Vasopressin and behaviour: from memory to olfaction. Regul Pept 45:121–125

    Article  CAS  PubMed  Google Scholar 

  • Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371(9624):1624–1632

    Article  CAS  PubMed  Google Scholar 

  • Dimson SB (1977) Desmopressin as a treatment for enuresis. Lancet 1(8024):1260

    Article  CAS  PubMed  Google Scholar 

  • Du Vigneaud V (1954) Hormones of the posterior pituitary gland: oxytocin and vasopressin. Harvey Lect 50:1–26

    Google Scholar 

  • Ecelbarger CA, Terris J, Frindt G, Echevarria M, Marples D, Nielsen S, Knepper MA (1995) Aquaporin-3 water channel localization and regulation in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 269:F663–F672

    CAS  Google Scholar 

  • Ecelbarger CA, Kim GH, Wade JB, Knepper MA (2001) Regulation of the abundance of renal sodium transporters and channels by vasopressin. Exp Neurol 171:227–234

    Article  CAS  PubMed  Google Scholar 

  • Echevarria M, Windhager EE, Tate SS, Frindt G (1994) Cloning and expression of AQP3, a water channel from the medullary collecting duct of rat kidney. Proc Natl Acad Sci USA 91:10997–11001

    Article  CAS  PubMed  Google Scholar 

  • Eckford SD, Swami KS, Jackson SR, Abrams PH (1994) Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 74(6):733–735

    Article  CAS  PubMed  Google Scholar 

  • Eckford SD, Carter PG, Jackson SR, Penney MD, Abrams P (1995) An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia. Br J Urol 76(4):459–463

    Article  CAS  PubMed  Google Scholar 

  • Egashira N, Mishima K, Iwasaki K, Oishi R, Fujiwara M (2009) New topics in vasopressin receptors and approach to novel drugs: Role of the vasopressin receptors in psychological and cognitive functions. J Pharmacol Sci 109:44–49

    Article  CAS  PubMed  Google Scholar 

  • Ferreira E, Letwin SR (1998) Desmopressin for nocturia and enuresis associated with multiple sclerosis. Ann Pharmacother 32(1):114–116

    Article  CAS  PubMed  Google Scholar 

  • Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O (1993) Pharmacokinetics of 1-deamino-8-d-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 38(2):177–182

    Article  CAS  Google Scholar 

  • Fredrikson S (1996) Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurol Scand 94(1):31–34

    Article  CAS  PubMed  Google Scholar 

  • Giminz I, Forbush B (2003) Short-term stimulation of the renal Na–K–Cl cotransporter (NKCC2) by vasopressin involves phosphorylation and membrane translocation of the protein. J Biol Chem 278:26946–26951

    Article  CAS  Google Scholar 

  • Goldsmith S (2006) Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure. Cleve Clin J Med 73(2):S20–S23

    Article  PubMed  Google Scholar 

  • Greenberg A (2000) Diuretic complications. Am J Med Sci 319:10

    Article  CAS  PubMed  Google Scholar 

  • Hashim H, Abrams P (2007) Novel uses for antidiuresis. Int J Clin Pract Suppl 155:32–36

    Article  PubMed  Google Scholar 

  • Hashim H, Malmberg L, Graugaard-Jensen C, Abrams P (2009) Desmopressin, as a ‘designer-drug’, in the treatment of overactive bladder syndrome. Neurourol Urodyn 28(1):40–46

    Article  CAS  PubMed  Google Scholar 

  • Hernando F, Schoots O, Lolait SJ, Burbach JP (2001) Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142(4):1659–1668

    Article  CAS  PubMed  Google Scholar 

  • Hilton P, Hertogs K, Stanton SL (1983) The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatr 46(9):854–855

    Article  CAS  PubMed  Google Scholar 

  • Hiroyama M, Aoyagi T, Fujiwara Y, Oshikawa S, Sanbe A, Endo F et al (2007a) Hyperammonemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume. J Physiol 581:1183–1192

    Article  CAS  PubMed  Google Scholar 

  • Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K et al (2007b) Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol 21:247–258

    Article  CAS  PubMed  Google Scholar 

  • Hjalmas K (1999) Desmopressin treatment: current status. Scand J Urol Nephrol Suppl 202:70–72

    Article  CAS  PubMed  Google Scholar 

  • Honda K, Takano Y (2009) New topics in vasopressin receptors and approach to novel drugs: Involvement of vasopressin V1a and V1b receptors in nociceptive responses and morphine-induced effects. J Pharmacol Sci 109:38–43

    Article  CAS  PubMed  Google Scholar 

  • Hoverd PA, Fowler CJ (1998) Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatr 65:778–780

    Article  CAS  PubMed  Google Scholar 

  • Hvistendahl GM, Riis A, Norgaard JP, Djurhuus JC (2005) The pharmacokinetics of 400 microg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int 95(6):804–809

    Article  CAS  PubMed  Google Scholar 

  • Insel PA, Tang CM, Hahntow I, Michel MC (2007) Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets – a review. Biochimica Biophysica Acta 1768:994–1005

    Article  CAS  Google Scholar 

  • Jackson EK (2006). Vasopressin and other agents affecting the renal conservation of water. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th edition. The McGraw-Hill companies. United States of America

    Google Scholar 

  • Janicic N, Verbalis JG (2003) Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 32:459–481

    Article  CAS  PubMed  Google Scholar 

  • Kimbrough RDJ, Cash WD, Branda LA, Chan WY, Du Vigneaud V (1963) Synthesis and biological properties of 1-desamino-8-lysine-vasopressin. J Biol Chem 238:1411–1414

    CAS  PubMed  Google Scholar 

  • Klug WS, Cummings MR (2000) Concepts of genetics, 6th edn. Prentice Hall, Upper Saddle River

    Google Scholar 

  • Knepper MA (1997) Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol Renal Physiol 272:F3–F12

    CAS  Google Scholar 

  • Knepper MA, Nielsen S, Chou CL, Digiovanni SR (1994) Mechanism of vasopressin action in the renal collecting duct. Semin Nephrol 14:302–321

    CAS  PubMed  Google Scholar 

  • Koshimizu A, Tsujimoto G (2009) New topics in vasopressin receptors and approach to novel drugs: Vasopressin and pain perception. J Pharmacol Sci 109:33–37

    Article  CAS  PubMed  Google Scholar 

  • Kronenberg HM, Melmed S, Polonsky KS (eds) (2002) Textbook of endocrinology, 10th edn. Elsevier, Philadelphia

    Google Scholar 

  • Kruse E, Uehlein N, Kaldenhoff R (2006) The aquaporins. Protein family review. Genome Biol 7(2):206.1–206.6

    Article  CAS  Google Scholar 

  • Kuo HC (2002) Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. Urology 59:485–489 (Level 2b)

    Article  PubMed  Google Scholar 

  • Lemmens-Gruber R, Kamyar M (2006) Vasopressin antagonists. Cell Mol Life Sci 63(15):1766–1779

    Article  CAS  PubMed  Google Scholar 

  • Lopes T, Dias JS, Marcelino J, Varela J, Ribeiro S, Dias J (2001) An assessment of the clinical efficacy of intranasal desmopressin spray in the treatment of renal colic. BJU Int 87(4):322–325

    Article  CAS  PubMed  Google Scholar 

  • Lose G, Mattiasson A, Walter S, Lalos O, van Kerrebroeck P, Abrams P, Freeman R (2004) Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 172(3):1021–1025

    Article  CAS  PubMed  Google Scholar 

  • Manning M, Stoev S, Cheng LL et al (1999) Discovery and design of novel vasopressin hypotensive peptide agonists. J Recept Signal Transduct Res 19:631–644

    Article  CAS  PubMed  Google Scholar 

  • Mansson W, Sundin T, Gullberg B (1980) Evaluation of a synthetic vasopressin analogue for treatment of nocturia in benign prostatic hypertrophy. A double-blind study. Scand J Urol Nephrol 14(2):139–141

    Article  CAS  PubMed  Google Scholar 

  • Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J (2002) Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 89(9):855–862 (Level 1b)

    Article  CAS  PubMed  Google Scholar 

  • Michell RH, Kirk CJ, Billah MM (1979) Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 7:861–865

    CAS  PubMed  Google Scholar 

  • Moro U, De Stefani S, Crisci A, De Antoni P, Scott CA, Selli C (1999) Evaluation of the effects of desmopressin in acute ureteral obstruction. Urol Int 62(1):8–11

    Article  CAS  PubMed  Google Scholar 

  • Nakamura S, Hirano T, Tsujimae K et al (2000) Antidiuretic effects of a nonpeptide vasopressin V2-receptor agonist OPC-51803 administered orally to rats. J Pharmacol Exp Ther 295:1005–1011

    CAS  PubMed  Google Scholar 

  • Nielsen S, Digiovanni SR, Christensen EI, Knepper MA, Harris HW (1993) Cellular and subcellular immunolocalization of vasopressin regulated water channel in rat kidney. Proc Natl Acad Sci USA 90:11663–11667

    Article  CAS  PubMed  Google Scholar 

  • Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokier J, Marples D (1999) Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 10:647–663

    CAS  PubMed  Google Scholar 

  • Nielsen S, Frokier J, Marples D, Kwon TH, Age P, Knepper M (2002) Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82:205–244

    CAS  PubMed  Google Scholar 

  • Norgaard JP, Pedersen EB, Djurhuus JC (1985) Diurnal anti-diuretic-hormone levels in enuretics. J Urol 134(5):1029–1031

    CAS  PubMed  Google Scholar 

  • O’Toole M (ed) (1992) Miller-Keane encyclopedia & dictionary of medicine, nursing & allied health, 5th edn. Saunders, Philadelphia

    Google Scholar 

  • Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ (2010) Guidelines on conservative treatment of non-neurogenic male LUTS. EAU Guidelines 3.5:23–25

    Google Scholar 

  • Ortega R, Ginès P, Uriz J et al (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36:941–948

    CAS  PubMed  Google Scholar 

  • Oshikawa S, Tanoue A, Koshimizu T, Kitagawa Y, Tsujimoto G (2004) Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol 65:623–629

    Article  CAS  PubMed  Google Scholar 

  • Padfield PL, Hodsman GP, Morton JJ (1978) Demeclocycline in the treatment of the syndrome of inappropriate antidiuretic hormone release: with measurement of plasma ADH. Postgrad Med J 54(635):623–627

    Article  CAS  PubMed  Google Scholar 

  • Palm C, Pistrosch F, Herbrig K, Gross P (2006) Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 119(7 Suppl 1):S87–S92

    Article  CAS  PubMed  Google Scholar 

  • Prasad S (2001). The role of the V2 vasopressin receptor in nephrogenic diabetes insipidus. Stanislaus Journal of biochemical reviews. http://wwwchem.csustan.edu/chem4400/sjbr/Prasad01.htm. Accessed on 26th July, 2009

  • Puri VN (1980) Urinary levels of antidiuretic hormone in nocturnal enuresis. Indian Pediatr 17(8):675–676

    CAS  PubMed  Google Scholar 

  • Rembratt A, Norgaard JP, Andersson KE (2003) Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 91(7):642–646 (Level 2b)

    Article  CAS  PubMed  Google Scholar 

  • Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard JP, Djurhuus JC (2004) Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55–70 years. Eur J Clin Pharmacol 60(6):397–402 (Level 2b)

    Article  CAS  PubMed  Google Scholar 

  • Rembratt A, Riis A, Norgaard JP (2006) Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 25(2):105–109 (Level 1b)

    Article  CAS  PubMed  Google Scholar 

  • Rittig S, Jensen AR, Jensen KT, Pedersen EB (1998) Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 48(2):235–241

    Article  CAS  Google Scholar 

  • Robinson D, Cardozo L, Akeson M, Hvistendahl G, Riis A, Norgaard JP (2004) Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 93(7):996–1000

    Article  CAS  PubMed  Google Scholar 

  • Roshani A, Falahatkar S, Khosropanah I, Roshan ZA, Zarkami T, Palizkar M, Emadi SA, Akbarpour M, Khaki N (2010) Assessment of clinical efficacy of intranasal desmopressin spray and diclofenac sodium suppository in treatment of renal colic versus diclofenac sodium alone. Urology 75(3):540–542

    Article  PubMed  Google Scholar 

  • Rovati GE, Capra V, Neubig RR (2007) The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71:959–964

    Article  CAS  PubMed  Google Scholar 

  • Sands JM (2003) Molecular mechanisms of urea transport. J Membr Biol 191:149–163

    Article  CAS  PubMed  Google Scholar 

  • Sands JM, Bichet DG (2006) Nephrogenic diabetes insipidus. Ann Intern Med 144:186–194

    CAS  PubMed  Google Scholar 

  • Schrier RW (2006) Water and sodium retention in oedematous disorders: role of vasopressin and aldosterone. Am J Med 119(7 Suppl 1):S47–S53

    Article  CAS  PubMed  Google Scholar 

  • Schulein R, Hermosilla R, Oksche A, Dehe M, Wiesner B et al (1998) A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS. M6 cells. Mol Pharmacol 54:525–535

    CAS  PubMed  Google Scholar 

  • Scott LV, Dinan TG (2002) Vasopressin as a target for antidepressant development: an assessment of the available evidence. J Affect Disord 72:113–124

    Article  CAS  PubMed  Google Scholar 

  • Serradeil-Le Gal C, Wagnon J, Valette G et al (2002a) Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 139:197–210

    Article  CAS  PubMed  Google Scholar 

  • Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G (2002b) Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 139:197–210

    Article  CAS  PubMed  Google Scholar 

  • Snyder HM, Noland TD, Breyer MD (1992) cAMP-dependent protein kinase mediates hydro-osmotic effect of vasopressin in collecting duct. Am J Physiol 263:C147–C153

    CAS  PubMed  Google Scholar 

  • Sonnenblick M, Friedlander Y, Rosin AJ (1993) Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 103:601–606

    Article  CAS  PubMed  Google Scholar 

  • Sorensen PS, Vilhardt H, Gjerris F, Warberg J (1984) Impermeability of the blood–cerebrospinal fluid barrier to 1-deamino-8-d-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. Eur J Clin Invest 14(6):435–439

    Article  CAS  PubMed  Google Scholar 

  • Stegner H, Artman HG, Leake RD, Fisher DA (1983) Does DDAVP (1-desamino-8-d-arginine-vasopressin) cross the blood–CSF barrier? Neuroendocrinology 37(4):262–265

    Article  CAS  PubMed  Google Scholar 

  • Studer RO, Cash WD (1963) Synthesis of 1-acetyl-8-argininevasopressin and a study of its effects in the rat pressor assay. J Biol Chem 238:657–659

    CAS  PubMed  Google Scholar 

  • Suchowersky O, Furtado S, Rohs G (1995) Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 10(3):337–340

    Article  CAS  PubMed  Google Scholar 

  • Terris J, Ecelbarger CA, Marples D, Knepper MA, Nielsen S (1995) Distribution of aquaporin-4 water channel expression within rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 269:F775–F785

    CAS  Google Scholar 

  • Terris J, Ecelbarger CA, Nielsen S, Knepper MA (1996) Long-term regulation of four renal aquaporins in rats. Am J Physiol Renal Physiol 271:F414–F422

    CAS  Google Scholar 

  • Thbonnier M, Coles P, Thibionnier A, Shoham M (2002) Molecular pharmacology and modelling of vasopressin receptors. Prog Brain Res 139:179–196

    Article  Google Scholar 

  • Tsujimoto G, Takano Y (2009) New topics in vasopressin receptors and approach to novel drugs: preface. J Pharmacol Sci 109:32

    Article  CAS  PubMed  Google Scholar 

  • Tubridy N et al (1999) Long term use of desmopressin for urinary symptoms in multiple sclerosis. Mult Scler 5:416–417

    CAS  PubMed  Google Scholar 

  • Turner RA, Pierce JG, Du Vigneaud V (1951) The purification and the amino acid content of vasopressin preparations. J Biol Chem 191(1):21–28

    CAS  PubMed  Google Scholar 

  • Tuvemo T (1978) DDAVP in childhood nocturnal enuresis. Acta Paediatr Scand 67(6):753–755

    Article  CAS  PubMed  Google Scholar 

  • Valiquette G, Abrams GM, Herbert J (1992) DDAVP in the management of nocturia in multiple sclerosis. Ann Neurol 31(5):577

    Article  CAS  PubMed  Google Scholar 

  • Valiquette G, Herbert J, Maede-D'Alisera P (1996) Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 53(12):1270–1275

    CAS  PubMed  Google Scholar 

  • Van de Walle J, Van Herzeele C, Raes A (2010) Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf 33(4):261–271

    Article  PubMed  Google Scholar 

  • Van Herzeele C, Alova I, Evans J, Eggert P, Lottmann H, Nørgaard JP, Vande Walle J (2009) Poor compliance with primary nocturnal enuresis therapy may contribute to insufficient desmopressin response. J Urol 182(4 Suppl):2045–2049

    Article  PubMed  CAS  Google Scholar 

  • Van Hoek AN, Yang B, Kirmiz S, Brown D (1998) Freeze-fracture analysis of plasma membranes of CHO cells stably expressing aquaporins 1–5. J Membr Biol 165:243–254

    Article  PubMed  Google Scholar 

  • van Kerrebroeck P, Rezapour M, Cortesse A, Thüroff J, Rijs A, Norgaard JP (2007) Desmopressin in the treatment of nocturia: a double blind placebo-controlled study. Eur Urol 52(1):221–229 (Level 1b)

    Article  PubMed  CAS  Google Scholar 

  • van Kerrebroeck P, Hashim H, Holm-Larsen T, Robinson D, Stanley N (2010) Thinking beyond the bladder: antidiuretic treatment of nocturia. Int J Clin Pract 64(6):807–816

    Article  PubMed  Google Scholar 

  • Vavra I, Machova A, Krejci I (1974) Antidiuretic action of 1-deamino-(8-d-arginine)-vasopressin in unanesthetized rats. J Pharmacol Exp Ther 188(1):241–247

    CAS  PubMed  Google Scholar 

  • Verbalis JG (2006) AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med 73(3):S24–S33

    Article  PubMed  Google Scholar 

  • Vilhardt H, Lundin S (1986) Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen Pharmacol 17(4):481–483

    CAS  PubMed  Google Scholar 

  • Vlavianos P, Westaby D (2001) Management of acute variceal haemorrhage. Eur J Gastroenterol Hepatol 13:335–342

    Article  CAS  PubMed  Google Scholar 

  • Vogt M, Lehnert T, Till H, Rolle U (2010) Evaluation of different modes of combined therapy in children with monosymptomatic nocturnal enuresis. BJU Int 105(10):1456–1459

    Article  PubMed  Google Scholar 

  • Walz T, Hirai T, Murata K, Heymann JB, Mitsuoka K, Fujiyoshi Y, Smith BL, Agre P, Engel A (1997) The three-dimensional structure of aquaporin-1. Nature 387:624–627

    Article  CAS  PubMed  Google Scholar 

  • Weatherall M (2004) The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol Urodyn 23(4):302–305 (Level 1a)

    Article  PubMed  Google Scholar 

  • Wuller S, Wiesner B, Loffler A, Furkert J, Krause G, Hermosilla R, Schaefer M, Schulein R, Rosenthal W, Oksche A (2004) Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem 279:47254–47263

    Article  PubMed  CAS  Google Scholar 

  • Yang B, Brown D, Verkman AS (1996) The mercurial insensitive water channel (AQP-4) forms orthogonal arrays in stably transfected Chinese hamster ovary cells. J Biol Chem 271:4577–4580

    Article  CAS  PubMed  Google Scholar 

  • Young LJ, Wang Z, Insel TR (1998) Neuroendocrine bases of monogamy. Trends Neurosci 21:71–75

    Article  CAS  PubMed  Google Scholar 

  • Young WS, Li J, Wersinger SR, Palkovits M (2006) The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience 143(4):1031–1039

    Article  CAS  PubMed  Google Scholar 

  • Zahariou A, Karamouti M, Karagiannis G, Papaioannou P (2008) Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Int Urol Nephrol 40(1):65–69

    Article  CAS  PubMed  Google Scholar 

  • Zerbe RL, Vinicor F, Robertson GL (1979) Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 28:503–508

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Cornwall Hospital, Truro, Cornwall, TR1 3UD, UK

    Sailaja Pisipati

  2. Bristol Urological Institute, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB, UK

    Hashim Hashim

Authors
  1. Sailaja Pisipati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hashim Hashim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hashim Hashim .

Editor information

Editors and Affiliations

  1. Wake Forest University, Medical Center Blvd., Winston-Salem, 27157-1088, North Carolina, USA

    Karl-Erik Andersson

  2. Academic Medical Center, Dept. Pharmacology & Pharmacotherapy, University of Amsterdam, Meibergdreef 15, Amsterdam, 1105 AZ, Netherlands

    Martin C. Michel

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pisipati, S., Hashim, H. (2011). Vasopressin Receptors in Voiding Dysfunction. In: Andersson, KE., Michel, M. (eds) Urinary Tract. Handbook of Experimental Pharmacology, vol 2011. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16499-6_21

Download citation

Publish with us

Policies and ethics

Search

Navigation